| Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. | |
| | |
MedLine Citation:
|
PMID: 14975476 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study aimed to investigate the impact of hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) therapy in patients with advanced heart failure (HF). BACKGROUND: Although statins are known to reduce mortality in coronary artery disease (CAD), the impact of statin therapy in patients with HF has not been well studied. Both the potential risks and benefits of statins in HF have been described. METHODS: We studied a cohort of 551 patients with systolic HF (left ventricular ejection fraction [EF] <or=40%) referred to a single university center for clinical management and/or transplant evaluation. Survival without the necessity of urgent heart transplantation was determined. RESULTS: The patients' mean age was 52 +/- 13 years; mean EF was 25 +/- 7%. Forty-five percent of the cohort had CAD, and 45% were receiving statin therapy, including 73% and 22% of CAD and non-CAD patients with HF, respectively. Patients receiving statins were significantly older and more likely to be male, with higher rates of hypertension, diabetes, and smoking. The EF and cholesterol levels were similar between treated and non-treated patients. Statin use was associated with improved survival without the necessity of urgent transplantation in both non-ischemic and ischemic HF patients (91% vs. 72%, p < 0.001 and 81% vs. 63%, p < 0.001 at one-year follow-up, respectively). After risk adjustment for age, gender, CAD, cholesterol, diabetes, medications, hemoglobin, creatinine, and New York Heart Association functional class, statin therapy remained an independent predictor of improved survival (hazard ratio 0.41 95% confidence interval 0.18 to 0.94). CONCLUSIONS: Statin therapy is associated with improved survival in patients with ischemic and non-ischemic HF. Randomized trials are needed for confirmation of a therapeutic benefit. |
| | |
Authors:
|
Tamara B Horwich; W Robb MacLellan; Gregg C Fonarow |
Related Documents
:
|
11520486 - Ongoing clinical trials of statins. 17601396 - Aggressive statin therapy for acute coronary syndromes. 16304326 - In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the ea... 16084176 - Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percut... 7666806 - Methods for improving the repeatability of automated ecg analysis. 23153406 - Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 43 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2004 Feb |
Date Detail:
|
Created Date: 2004-02-20 Completed Date: 2004-03-12 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 642-8 Citation Subset: AIM; IM |
Affiliation:
|
Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California 90095-1679, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cohort Studies Female Follow-Up Studies Heart Failure / drug therapy*, etiology, mortality* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Male Middle Aged Survival Analysis Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission ...
Next Document: Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of cor...